GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Constellation Pharmaceuticals Inc (NAS:CNST) » Definitions » EBITDA Margin %

Constellation Pharmaceuticals (Constellation Pharmaceuticals) EBITDA Margin % : 0.00% (As of Mar. 2021)


View and export this data going back to 2018. Start your Free Trial

What is Constellation Pharmaceuticals EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Constellation Pharmaceuticals's EBITDA for the three months ended in Mar. 2021 was $-39.87 Mil. Constellation Pharmaceuticals's Revenue for the three months ended in Mar. 2021 was $0.00 Mil. Therefore, Constellation Pharmaceuticals's EBITDA margin for the quarter that ended in Mar. 2021 was 0.00%.


Constellation Pharmaceuticals EBITDA Margin % Historical Data

The historical data trend for Constellation Pharmaceuticals's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Constellation Pharmaceuticals EBITDA Margin % Chart

Constellation Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20
EBITDA Margin %
- - - - -

Constellation Pharmaceuticals Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Constellation Pharmaceuticals's EBITDA Margin %

For the Biotechnology subindustry, Constellation Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Constellation Pharmaceuticals's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Constellation Pharmaceuticals's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Constellation Pharmaceuticals's EBITDA Margin % falls into.



Constellation Pharmaceuticals EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Constellation Pharmaceuticals's EBITDA Margin % for the fiscal year that ended in Dec. 2020 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2020 )/Revenue (A: Dec. 2020 )
=-122.812/0
= %

Constellation Pharmaceuticals's EBITDA Margin % for the quarter that ended in Mar. 2021 is calculated as

EBITDA Margin %=EBITDA (Q: Mar. 2021 )/Revenue (Q: Mar. 2021 )
=-39.87/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Constellation Pharmaceuticals  (NAS:CNST) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Constellation Pharmaceuticals EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Constellation Pharmaceuticals's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Constellation Pharmaceuticals (Constellation Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
215 First Street, Suite 200, Cambridge, MA, USA, 02142
Constellation Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead products include CPI-0610, which is a small molecule designed to promote anti-tumor activity by specifically inhibiting the function of BET proteins, which normally enhance target gene expression, and CPI-1205 which is a small molecule designed to promote anti-tumor activity by specifically inhibiting EZH2, an enzyme that suppresses target gene expression. It operates in the segment of the development of novel therapeutics in the field of epigenetics.
Executives
Emma Reeve officer: Chief Financial Officer C/O PAREXEL INTERNATIONAL CORPORATION, 195 WEST STREET, WALTHAM MA 02451
Column Group L P 10 percent owner 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Karen Valentine officer: See Remarks C/O ANTIGENICS INC., 3 FORBES RD, LEXINGTON MA 02421
Mark A Goldsmith director, 10 percent owner 925 PAGE MILL ROAD, PALO ALTO CA 94304
Jeffrey Humphrey officer: Chief Medical Officer C/O CONSTELLATION PHARMACEUTICALS, INC., 215 FIRST STREET, SUITE 200, CAMBRIDGE MA 02142
Steven L. Hoerter director C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Elizabeth Trehu director C/O JOUNCE THERAPEUTICS, INC., 1030 MASSACHUSETTS AVENUE, CAMBRIDGE MA 02138
Scott Braunstein director C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
James E Audia director 215 FIRST STREET, SUITE 200 CAMBRIDGE MA 02142
Adrian Senderowicz officer: Chief Medical Officer C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Jigar Raythatha director, officer: See Remarks C/O JOUNCE THERAPEUTICS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Patrick Trojer officer: Chief Scientific Officer 215 FIRST STREET SUITE 200 CAMBRIDGE MA 02142
Richard S Levy director 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Ponoi Management, Llc 10 percent owner, other: General Partner 1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
David V Goeddel 10 percent owner, other: Managing Partner C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158